Leerink analyst Faisal Khurshid raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $107 and keeps an Outperform rating on the shares. The firm is “impressed” with the strength of Icotyde’s label and believes the approval will fund its pipeline well into the future.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
- Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
- Protagonist Therapeutics price target raised to $125 from $115 at Citi
- Protagonist Therapeutics price target raised to $119 from $113 at Barclays
- Protagonist Therapeutics price target raised to $104 from $91 at Clear Street